Compare ILMN & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ILMN | IQV |
|---|---|---|
| Founded | 1998 | 1982 |
| Country | United States | United States |
| Employees | 8650 | 93000 |
| Industry | Medical Specialities | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.0B | 43.1B |
| IPO Year | 2000 | 2013 |
| Metric | ILMN | IQV |
|---|---|---|
| Price | $238.46 | $266.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 16 |
| Target Price | $124.24 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 2.0M | 1.3M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.87 | 4.67 |
| EPS | ★ 2.22 | 1.61 |
| Revenue | $4,343,000,000.00 | ★ $9,739,000,000.00 |
| Revenue This Year | $6.47 | $6.77 |
| Revenue Next Year | $5.58 | $5.89 |
| P/E Ratio | ★ $110.44 | $167.35 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $88.00 | $154.50 |
| 52 Week High | $246.76 | $273.88 |
| Indicator | ILMN | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 63.35 |
| Support Level | $116.43 | $252.53 |
| Resistance Level | N/A | $271.80 |
| Average True Range (ATR) | 9.25 | 6.26 |
| MACD | 2.28 | -0.85 |
| Stochastic Oscillator | 77.18 | 67.87 |
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.